Literature DB >> 15520815

Drugs as materials: valuing physical form in drug discovery.

Colin R Gardner1, Christopher T Walsh, Orn Almarsson.   

Abstract

Traditionally, potency and selectivity (and to some extent metabolism) have been the key parameters to consider in the process of discovering new drug candidates. Recently, heads of research and CEOs have been learning a new reality: drugs can move around the body and act at the molecular level, but the chemical and material properties of their physical form need to be identified and optimized for in vivo performance, reliable manufacture and the protection of intellectual property. This review discusses the challenge of pharmaceutical materials discovery, and suggests strategies for addressing the characterization and evaluation of physico-chemical and material properties in the drug discovery and development process.

Mesh:

Substances:

Year:  2004        PMID: 15520815     DOI: 10.1038/nrd1550

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN: 1474-1776            Impact factor:   84.694


  34 in total

1.  Solubility at the molecular level: development of a critical aggregation concentration (CAC) assay for estimating compound monomer solubility.

Authors:  Jie Wang; Edmund Matayoshi
Journal:  Pharm Res       Date:  2012-03-16       Impact factor: 4.200

2.  Crystal morphology engineering of pharmaceutical solids: tabletting performance enhancement.

Authors:  Sabiruddin Mirza; Inna Miroshnyk; Jyrki Heinämäki; Osmo Antikainen; Jukka Rantanen; Pia Vuorela; Heikki Vuorela; Jouko Yliruusi
Journal:  AAPS PharmSciTech       Date:  2009-01-30       Impact factor: 3.246

3.  Downscaling drug nanosuspension production: processing aspects and physicochemical characterization.

Authors:  Bernard Van Eerdenbrugh; Bernard Stuyven; Ludo Froyen; Jan Van Humbeeck; Johan A Martens; Patrick Augustijns; Guy Van den Mooter
Journal:  AAPS PharmSciTech       Date:  2009-01-16       Impact factor: 3.246

4.  The preparation and evaluation of water-soluble SKLB610 nanosuspensions with improved bioavailability.

Authors:  Yunchuang Huang; Xun Luo; Xinyu You; Yong Xia; Xuejiao Song; Luoting Yu
Journal:  AAPS PharmSciTech       Date:  2013-08-10       Impact factor: 3.246

5.  Crystal structure determination of new antimitotic agent bis(p-fluorobenzyl)trisulfide.

Authors:  Haoyun An; Xiurong Hu; Jianming Gu; Linshen Chen; Weiming Xu; Xiaopeng Mo; Wanhong Xu; Xiaobo Wang; Xiao Xu
Journal:  AAPS PharmSciTech       Date:  2008-04-22       Impact factor: 3.246

6.  Getting physical to fix pharma.

Authors:  Patrick R Connelly; T Minh Vuong; Mark A Murcko
Journal:  Nat Chem       Date:  2011-08-23       Impact factor: 24.427

Review 7.  Pharmaceutical Cocrystals: Regulatory and Strategic Aspects, Design and Development.

Authors:  Dipak Dilip Gadade; Sanjay Sudhakar Pekamwar
Journal:  Adv Pharm Bull       Date:  2016-12-22

8.  Nano-extrusion: a one-step process for manufacturing of solid nanoparticle formulations directly from the liquid phase.

Authors:  Johannes Khinast; Ramona Baumgartner; Eva Roblegg
Journal:  AAPS PharmSciTech       Date:  2013-03-06       Impact factor: 3.246

9.  The twofold advantage of the amorphous form as an oral drug delivery practice for lipophilic compounds: increased apparent solubility and drug flux through the intestinal membrane.

Authors:  Arik Dahan; Avital Beig; Viktoriya Ioffe-Dahan; Riad Agbaria; Jonathan M Miller
Journal:  AAPS J       Date:  2012-12-15       Impact factor: 4.009

10.  Co-crystals: a novel approach to modify physicochemical properties of active pharmaceutical ingredients.

Authors:  A V Yadav; A S Shete; A P Dabke; P V Kulkarni; S S Sakhare
Journal:  Indian J Pharm Sci       Date:  2009-07       Impact factor: 0.975

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.